<DOC>
	<DOC>NCT00329173</DOC>
	<brief_summary>To compare reduction of LDL-C and safety between 10mg rosuvastatin and 20mg atorvastatin after 6 weeks treatment</brief_summary>
	<brief_title>PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male or female 18 or over. A history of CHD or clinical evidence of atherosclerosis (diabetic or nondiabetic) or a CHD risk equivalent (10year risk score &gt; 20% for CHD as described in NCEP ATP III guidelines1. History of statin induced myopathy, or serious hypersensitivity reaction to other HMGCoA reductase inhibitors (statins), including rosuvastatin Pregnancy History of homozygous familial hypercholesterolaemia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>